109 related articles for article (PubMed ID: 23221629)
1. Twelve week post-treatment undetectable hepatitis C virus (HCV)-RNA by PCR assay predicts a sustained virological response to anti-HCV therapy independently from immunological status of the infected patients.
Donato MF; Bastiampillai AJ; Manini M; Monico S
J Antimicrob Chemother; 2013 Apr; 68(4):974-5. PubMed ID: 23221629
[No Abstract] [Full Text] [Related]
2. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load.
Akuta N; Suzuki F; Sezaki H; Suzuki Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Watahiki S; Sato J; Kobayashi M; Arase Y; Ikeda K; Kumada H
J Med Virol; 2006 Jan; 78(1):83-90. PubMed ID: 16299715
[TBL] [Abstract][Full Text] [Related]
3. Virological tools to diagnose and monitor hepatitis C virus infection.
Chevaliez S
Clin Microbiol Infect; 2011 Feb; 17(2):116-21. PubMed ID: 21054664
[TBL] [Abstract][Full Text] [Related]
4. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C.
Abdelmalek MF; Firpi RJ; Soldevila-Pico C; Reed AI; Hemming AW; Liu C; Crawford JM; Davis GL; Nelson DR
Liver Transpl; 2004 Feb; 10(2):199-207. PubMed ID: 14762857
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis C virus RNA load in relapsed patients: week two of treatment is the best time to predict the complete response.
Halfon P; Khiri H; Tran A; Pénaranda G; Courcambeck J; Joly H; Ouzan D
Eur J Gastroenterol Hepatol; 2003 Oct; 15(10):1067-71. PubMed ID: 14501613
[TBL] [Abstract][Full Text] [Related]
6. Therapy-induced clearance of HCV core antigen from plasma predicts an end of treatment viral response.
Tedder RS; Tuke P; Wallis N; Wright M; Nicholson L; Grant PR
J Viral Hepat; 2013 Jan; 20(1):65-71. PubMed ID: 23231086
[TBL] [Abstract][Full Text] [Related]
7. Response to combined interferon and ribavirin is better in patients infected with hepatitis C virus genotype 6 than genotype 1 in Hong Kong.
Yuen MF; Lai CL
Intervirology; 2006; 49(1-2):96-8. PubMed ID: 16166796
[TBL] [Abstract][Full Text] [Related]
8. Frequency of very low HCV viremia detected by a highly sensitive HCV-RNA assay.
Fytili P; Tiemann C; Wang C; Schulz S; Schaffer S; Manns MP; Wedemeyer H
J Clin Virol; 2007 Aug; 39(4):308-11. PubMed ID: 17625963
[TBL] [Abstract][Full Text] [Related]
9. [Current and future applications of viral clearance kinetics in the treatment of hepatitis C].
Buti M
Gastroenterol Hepatol; 2004 Feb; 27 Suppl 1():24-9. PubMed ID: 15195531
[No Abstract] [Full Text] [Related]
10. Ribavirin priming improves the virological response to antiviral treatment in transplanted patients with recurrent hepatitis C: a pilot study.
Merli M; Giannelli V; Gentili F; Giusto M; Simmaco M; Lionetto L; Corradini SG; Biliotti E; Attili AF; Rossi M; Taliani G
Antivir Ther; 2011; 16(6):879-85. PubMed ID: 21900720
[TBL] [Abstract][Full Text] [Related]
11. Performance evaluation of the Artus hepatitis C virus QS-RGQ assay.
Paba P; Fabeni L; Perno CF; Ciotti M
J Virol Methods; 2012 Jan; 179(1):77-80. PubMed ID: 22001273
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the clinical usefulness of COBAS AMPLICOR HCV MONITOR assay (ver2.0): Comparison with AMPLICOR HCV MONITOR assay (ver1.0) and HCV core protein level.
Kawai S; Yokosuka O; Imazeki F; Saisho H; Mizuno C
J Med Virol; 2002 Nov; 68(3):343-51. PubMed ID: 12226820
[TBL] [Abstract][Full Text] [Related]
13. HCV RNA viral load assessments in the era of direct-acting antivirals.
Cobb B; Pockros PJ; Vilchez RA; Vierling JM
Am J Gastroenterol; 2013 Apr; 108(4):471-5. PubMed ID: 23552304
[TBL] [Abstract][Full Text] [Related]
14. HCV RNA quantification with different assays: implications for protease-inhibitor-based response-guided therapy.
Fevery B; Susser S; Lenz O; Cloherty G; Perner D; Picchio G; Sarrazin C
Antivir Ther; 2014; 19(6):559-67. PubMed ID: 24584086
[TBL] [Abstract][Full Text] [Related]
15. Ribavirin/interferon-alpha sequential treatment of recurrent hepatitis C after liver transplantation.
Giostra E; Kullak-Ublick GA; Keller W; Fried R; Vanlemmens C; Kraehenbuhl S; Locher S; Egger HP; Clavien PA; Hadengue A; Mentha G; Morel P; Negro F
Transpl Int; 2004 May; 17(4):169-76. PubMed ID: 15060764
[TBL] [Abstract][Full Text] [Related]
16. Modulation of epitope-specific anti-hepatitis C virus E2 (anti-HCV/E2) antibodies by anti-viral treatment.
Mancini N; Carletti S; Perotti M; Romanò L; Craxì RD; Craxì A; Zanetti AR; Clementi M; Burioni R
J Med Virol; 2006 Oct; 78(10):1304-11. PubMed ID: 16927283
[TBL] [Abstract][Full Text] [Related]
17. [Evaluating the efficacy of interferon therapy on hepatitis C patients].
Shiraha H; Iwasaki Y; Shiratori Y
Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):489-92. PubMed ID: 15359847
[No Abstract] [Full Text] [Related]
18. Complete eradication of hepatitis C virus after interferon treatment for chronic hepatitis C.
De Mitri MS; Morsica G; Chen CH; Mele L; Baccarini P; Chianese R; Piccinini A; Lazzarin A; Pisi E
Ital J Gastroenterol Hepatol; 1997 Jun; 29(3):255-61. PubMed ID: 9646218
[TBL] [Abstract][Full Text] [Related]
19. Early prediction of hepatitis C virus (HCV) infection relapse in nonresponders to primary interferon therapy by means of HCV RNA whole-blood analysis.
Watkins-Riedel T; Ferenci P; Steindl-Munda P; Gschwantler M; Mueller C; Woegerbauer M
Clin Infect Dis; 2004 Dec; 39(12):1754-60. PubMed ID: 15578395
[TBL] [Abstract][Full Text] [Related]
20. Transient reappearance of serum hepatitis C virus RNA observed by real-time PCR during antiviral therapy with peginterferon and ribavirin: Reappearance of references published in 2005-2009.
Gelderblom HC; Beld MG
J Clin Virol; 2010 Jun; 48(2):150-1; author reply 152. PubMed ID: 20347385
[No Abstract] [Full Text] [Related]
[Next] [New Search]
